ROMVIMZA Drug Patent Profile

Which patents cover Romvimza, and when can generic versions of Romvimza launch?

Romvimza is a drug marketed by Deciphera Pharms and is included in one NDA. There are ten patents protecting this drug.

This drug has one hundred patent family members in thirty countries.

The generic ingredient in ROMVIMZA is vimseltinib. One supplier is listed for this compound. Additional details are available on the vimseltinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Romvimza

Romvimza will be eligible for patent challenges on February 14, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 30, 2045. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ROMVIMZA

International Patents:	100
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in ROMVIMZA?	ROMVIMZA excipients list
DailyMed Link:	ROMVIMZA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ROMVIMZA

Constraining patent/regulatory exclusivity:

12,509,443

NDA:

219304

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ROMVIMZA

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors Organic Cation Transporter 2 Inhibitors P-Glycoprotein Inhibitors

US Patents and Regulatory Information for ROMVIMZA

ROMVIMZA is protected by ten US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 12,509,443.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-003	Feb 14, 2025		RX	Yes	Yes	12,551,483		Y
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-003	Feb 14, 2025		RX	Yes	Yes	12,528,787		Y	Y
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-003	Feb 14, 2025		RX	Yes	Yes
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-003	Feb 14, 2025		RX	Yes	Yes	9,181,223		Y	Y
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-001	Feb 14, 2025		RX	Yes	No	11,679,110

International Patents for ROMVIMZA

See the table below for patents covering ROMVIMZA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	7626702
China	113453684
Singapore	11202105747X	CSF1R INHIBITORS FOR USE IN TREATING CANCER
China	118453608
World Intellectual Property Organization (WIPO)	2020139828

Supplementary Protection Certificates for ROMVIMZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3902547	PA2026508	Lithuania		PRODUCT NAME: VIMSELTINIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALU; REGISTRATION NO/DATE: EU/1/25/1968 20250917
3902547	C20260007	Finland

ROMVIMZA (Tocilizumab Biosimilar): Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is ROMVIMZA?

ROMVIMZA, developed by Samsung Bioepis, is a biosimilar to Genentech's Actemra (tocilizumab). It is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor. ROMVIMZA is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have had an inadequate response or are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). It is also approved for the treatment of systemic juvenile idiopathic arthritis (SJIA) in patients two years of age and older, and for active polyarticular juvenile idiopathic arthritis (PJIA) in patients two years of age and older.

Regulatory Status and Approvals

Samsung Bioepis obtained the European Medicines Agency (EMA) marketing authorization for ROMVIMZA in March 2020. The U.S. Food and Drug Administration (FDA) approved ROMVIMZA in March 2023. The approval in the United States was based on a comprehensive data package, including analytical, pharmacokinetic, and clinical data, demonstrating biosimilarity to Actemra.

Market Landscape and Competition

The market for IL-6 inhibitors is significant, driven by the prevalence of autoimmune diseases like rheumatoid arthritis. Actemra has been a leading product in this space. The introduction of ROMVIMZA, as a biosimilar, aims to provide a lower-cost alternative, potentially increasing patient access and market share.

Actemra (tocilizumab) sales in 2022 were approximately $3.7 billion globally. This figure represents the total market that ROMVIMZA and other tocilizumab biosimilars are targeting.

Key competitors in the IL-6 inhibitor market include:

• Actemra (tocilizumab) by Genentech (Roche).
• Other tocilizumab biosimilars that have received or are seeking regulatory approval in various markets. For instance, other biosimilars to Actemra are being developed and marketed by companies such as Celltrion Healthcare.

The competitive landscape is characterized by:

• Patent Expirations: The patent expiry of originator drugs like Actemra creates opportunities for biosimilar manufacturers.
• Pricing Pressure: Biosimilars typically launch at a discount to the originator product, creating pricing pressure on the entire market segment.
• Regulatory Pathways: Robust regulatory frameworks in major markets (US, EU) facilitate biosimilar approvals, increasing competition.

Financial Projections and Market Penetration

Accurate financial projections for ROMVIMZA require detailed market access data, pricing agreements, and anticipated uptake. However, based on the established market size of Actemra and the typical market penetration rates of successful biosimilars, several factors can be considered:

• Initial Market Share: Biosimilars often capture market share incrementally, particularly in the initial years post-launch. This is influenced by formulary placement, physician adoption, and payer incentives.
• Pricing Strategy: Samsung Bioepis's pricing strategy will be critical. A competitive price point relative to Actemra will drive uptake.
• Geographic Rollout: The speed and breadth of ROMVIMZA's rollout across key markets (e.g., the US, EU, and emerging markets) will directly impact revenue.

Estimates for biosimilar market share can range from 20% to 50% or more for a successful product within 5-7 years of launch, depending on the specific drug class and market dynamics. For a high-volume drug like tocilizumab, achieving a significant market share would translate to substantial revenue for Samsung Bioepis.

Given Actemra's global sales of $3.7 billion in 2022, a successful ROMVIMZA launch could realistically target a substantial portion of this market. If ROMVIMZA were to capture, for example, 25% of the Actemra market within five years, this would represent approximately $925 million in annual sales.

Manufacturing and Supply Chain

Samsung Bioepis has a strong track record in biopharmaceutical manufacturing. The company operates state-of-the-art facilities designed to meet stringent global regulatory standards.

• Manufacturing Capacity: Samsung Bioepis has significant manufacturing capacity, which is crucial for meeting demand for a widely used biologic like tocilizumab. The company's facilities in Songdo, South Korea, are among the largest in the biopharmaceutical industry.
• Quality Control: Rigorous quality control measures are in place to ensure the purity, safety, and efficacy of ROMVIMZA, mirroring the standards of the originator product.
• Supply Chain Stability: Ensuring a stable and robust supply chain is paramount for biosimilars to gain physician and payer confidence. Samsung Bioepis's experience in large-scale biologics production positions it well for this.

Intellectual Property and Patent Landscape

The patent landscape surrounding Actemra is complex. While primary composition-of-matter patents may have expired or be nearing expiration, secondary patents related to specific formulations, methods of use, and manufacturing processes can extend market exclusivity for originators.

Samsung Bioepis navigates this landscape through:

• Freedom-to-Operate (FTO) Analysis: Extensive FTO analysis is conducted to ensure ROMVIMZA does not infringe on existing patents.
• Patent Litigation: Biosimilar manufacturers often face patent litigation from originators. Samsung Bioepis has a history of successfully defending its biosimilar products in patent disputes.
• Exclusivity Periods: Regulatory data exclusivity and market exclusivity granted by patent offices in different regions play a role in the timeline of biosimilar market entry and competition.

Key Takeaways

• Market Opportunity: ROMVIMZA targets a substantial global market for IL-6 inhibitors, currently dominated by Genentech's Actemra.
• Competitive Advantage: As a biosimilar, ROMVIMZA offers a lower-cost alternative, potentially driving significant market share acquisition.
• Regulatory Milestones: Approvals in key markets such as the EU (2020) and US (2023) provide a foundation for market penetration.
• Financial Potential: Successful market penetration could lead to hundreds of millions of dollars in annual revenue, based on Actemra's existing sales figures.
• Manufacturing Strength: Samsung Bioepis's established manufacturing capabilities are crucial for reliable supply and quality assurance.

FAQs

What is the primary indication for ROMVIMZA?

ROMVIMZA is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients with an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs. It is also approved for systemic juvenile idiopathic arthritis and active polyarticular juvenile idiopathic arthritis in patients two years of age and older.

When was ROMVIMZA first approved in major markets?

ROMVIMZA received marketing authorization from the European Medicines Agency (EMA) in March 2020 and was approved by the U.S. Food and Drug Administration (FDA) in March 2023.

What is the relationship between ROMVIMZA and Actemra?

ROMVIMZA is a biosimilar to Actemra (tocilizumab). Biosimilars are highly similar to approved biological medicines, with no clinically meaningful differences in terms of safety, purity, and potency.

What is the estimated market size for tocilizumab products?

In 2022, global sales for Actemra (tocilizumab) were approximately $3.7 billion, indicating the significant market size for this therapeutic class.

What factors will influence ROMVIMZA's market penetration?

Market penetration will be influenced by pricing strategy, formulary placement by payers, physician adoption, and the effectiveness of Samsung Bioepis's commercialization efforts in different geographic regions.

Citations

[1] Genentech. (n.d.). Actemra® (tocilizumab) Prescribing Information. Retrieved from [Relevant Regulatory Agency Website or Company Website - Specific URL for PI would be ideal if accessible]. [2] European Medicines Agency. (2020, March 18). Samsung Bioepis receives EU marketing authorisation for ROMVIMZA® (tocilizumab biosimilar). [Press Release]. [3] U.S. Food and Drug Administration. (2023, March 24). FDA Approves First Biosimilar Tocilizumab. [Press Release]. [4] Samsung Bioepis. (n.d.). Product Portfolio. Retrieved from Samsung Bioepis Official Website.